How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

2,713 results for

Quetiapine

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

21. Lamotrigine, quetiapine and folic acid for bipolar depression: the CEQUEL trial

Lamotrigine, quetiapine and folic acid for bipolar depression: the CEQUEL trial Lamotrigine, quetiapine and folic acid for bipolar depression Search National Elf Service Search National Elf Service » » » » Lamotrigine, quetiapine and folic acid for bipolar depression: the CEQUEL trial Jan 25 2016 Posted by Conflict of Interest: I must state that I am a long-time colleague of John Geddes and his group at Oxford, having been an investigator in the BALANCE trial and one of the authors of its main (...) publication. In addition I have been a paid advisor to Sunovion, whose drug lurasidone is an approved treatment in the US for bipolar depression. Amongst people with bipolar disorder, depression seems to be the predominant mood problem (much more than mania or hypomania) and there aren’t many effective treatments for it (Judd LL, et al, 2002). Most of the treatments with established efficacy for bipolar depression (quetiapine, lurasidone, and olanzapine combined with fluoxetine) benefit from a typically

2016 The Mental Elf

22. Cost effectiveness of quetiapine in patients with acute bipolar depression and in maintenance treatment after an acute depressive episode

Cost effectiveness of quetiapine in patients with acute bipolar depression and in maintenance treatment after an acute depressive episode Cost effectiveness of quetiapine in patients with acute bipolar depression and in maintenance treatment after an acute depressive episode Cost effectiveness of quetiapine in patients with acute bipolar depression and in maintenance treatment after an acute depressive episode Ekman M, Lindgren P, Miltenburger C, Meier G, Locklear JC, Chatterton ML Record (...) Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary The study examined the cost-effectiveness of pharmacological treatments in all phases of bipolar disorder, comparing quetiapine with olanzapine and olanzapine plus lithium as well as with other

2013 NHS Economic Evaluation Database.

23. Comparing tolerability profile of quetiapine, risperidone, aripiprazole and ziprasidone in schizophrenia and affective disorders: a meta-analysis

Comparing tolerability profile of quetiapine, risperidone, aripiprazole and ziprasidone in schizophrenia and affective disorders: a meta-analysis Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2013 DARE.

24. Important drug interaction involving phenytoin and quetiapine (PubMed)

Important drug interaction involving phenytoin and quetiapine To describe a patient case in which a drug interaction involving quetiapine and phenytoin resulted in an absence of clinical response and serum quetiapine levels below the point of detection.This patient was on concurrent phenytoin, valproic acid, and quetiapine therapy for 10 months. Prior to discontinuing phenytoin, a serum quetiapine level was found to be less than 10 ng/mL. It took approximately 1 month after phenytoin's (...) discontinuation for quetiapine levels to attain measurable concentrations. The patient's clinical response to quetiapine improved significantly after this interaction resolved.Phenytoin is an inducer of cytochrome P450 3A4, and quetiapine is a substrate of this enzyme. Patients on concurrent phenytoin and quetiapine therapy may require monitoring of quetiapine concentrations, which is often not routine practice, as this drug interaction can result in a clinically significant reduction in quetiapine levels

Full Text available with Trip Pro

2018 The Mental Health Clinician

25. Atypical Neuroleptic Malignant Syndrome Precipitated by Clozapine and Quetiapine Overdose: A Diagnostic Challenge (PubMed)

Atypical Neuroleptic Malignant Syndrome Precipitated by Clozapine and Quetiapine Overdose: A Diagnostic Challenge Neuroleptic malignant syndrome (NMS) is a rare, idiosyncratic, but life-threatening adverse reaction associated with the use of antipsychotic drugs. It is characterized by a tetrad of fever, rigidity, autonomic instability, and altered mental status. Failure to diagnose NMS early and institute appropriate treatment can result in serious medical complications and death. While (...) diagnostic criteria for NMS exist, atypical presentations that lack one or more characteristic features pose a diagnostic dilemma to clinicians. The concept of atypical NMS has been proposed for such cases but remains controversial. We report a case of atypical NMS associated with overdose on clozapine and quetiapine and discuss the diagnostic challenges of an atypical presentation. In this case, the diagnosis was delayed due to the absence of rigidity, but later made after serum creatine kinase

Full Text available with Trip Pro

2018 Innovations in clinical neuroscience

26. A Lack of Systemic Absorption Following the Repeated Application of Topical Quetiapine in Healthy Adults. (PubMed)

A Lack of Systemic Absorption Following the Repeated Application of Topical Quetiapine in Healthy Adults. In the absence of suitable oral or intravenous access for medication administration and when the intramuscular medications are undesirable, alternative routes for drug delivery may be considered. Antipsychotics administered via an inhaled, intranasal, rectal, or topical route have been described in the literature. Topically administered antipsychotics have been previously reported (...) antipsychotic may result in detectable serum levels in an accumulating fashion, a pharmacokinetic study was conducted. Five healthy, adult participants consented to receive extemporaneously prepared topical quetiapine in Lipoderm every 4 hours for a total of 5 doses. Blood samples were drawn at baseline and hours 2, 4, 8, 12, 16, and 24, and serum quetiapine concentrations were measured using high-performance liquid chromatography. Quetiapine was undetectable in every sample from 3 participants. Two

2018 American Journal of Hospice and Palliative Medicine

27. Clinical Trial With Quetiapine Prophylaxis Postoperative Delirium in High Risk Surgical Patients

Clinical Trial With Quetiapine Prophylaxis Postoperative Delirium in High Risk Surgical Patients Clinical Trial With Quetiapine Prophylaxis Postoperative Delirium in High Risk Surgical Patients - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one (...) or more studies before adding more. Clinical Trial With Quetiapine Prophylaxis Postoperative Delirium in High Risk Surgical Patients The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. of clinical studies and talk to your health care provider before participating. Read our for details. ClinicalTrials.gov Identifier: NCT03739476 Recruitment Status : Recruiting

2018 Clinical Trials

28. Quetiapine Excretion Into Human Breast Milk. (PubMed)

Quetiapine Excretion Into Human Breast Milk. Risk assessment of the use of quetiapine during breastfeeding is challenging owing to a paucity of data.A pharmacokinetic study was conducted in lactating women who were taking quetiapine. The primary endpoint was to determine quetiapine concentration profiles in milk and estimated infant exposure levels. Multiple milk and a single blood quetiapine concentrations were determined using a highly sensitive liquid chromatography with tandem mass (...) spectroscopy method.Nine subjects receiving fast-release quetiapine (mean dose, 41 mg/d) were analyzed at steady state. The mean milk/plasma drug concentration ratio at 2-hour postdose was 0.47 (SD, 0.50; range, 0.13-1.67). The mean milk concentration of each patient was 5.7 ng/mL (SD, 4.5; range, 1.4-13.9 ng/mL). The mean infant quetiapine dose via milk per body weight relative to weight-adjusted maternal dose was 0.16 % (SD, 0.08; range, 0.04%-0.35%).Infant exposure levels to quetiapine via milk

2018 Journal of Clinical Psychopharmacology

29. Hospitalization outcomes in patients with schizophrenia after switching to lurasidone or quetiapine: a US claims database analysis. (PubMed)

Hospitalization outcomes in patients with schizophrenia after switching to lurasidone or quetiapine: a US claims database analysis. This study compared hospital admission rates among adult patients with schizophrenia who switched to antipsychotic monotherapy with lurasidone or quetiapine.This retrospective cohort study used U.S.-based Truven Health MarketScan® Medicaid Multi-State Database (April 2010 through December 2012) and MarketScan® Commercial Claims and Encounters Database (April 2010 (...) through October 2013). Continuous enrollment for 6-months before and after medication initiation was required. Treatment episodes ended after 6-months post lurasidone or quetiapine initiation, a 60-day treatment gap, or initiation of another antipsychotic. Length of treatment episodes (i.e., treatment duration) was compared using a t-test. All-cause, mental-health, and schizophrenia-related hospitalization rates, as well as costs, were compared between lurasidone- and quetiapine-treated patients using

Full Text available with Trip Pro

2018 BMC health services research

30. Pharmacokinetic evaluation of quetiapine fumarate controlled release hybrid hydrogel: a healthier treatment of schizophrenia (PubMed)

Pharmacokinetic evaluation of quetiapine fumarate controlled release hybrid hydrogel: a healthier treatment of schizophrenia The current study aimed to rationally develop and characterize pH-sensitive controlled release hydrogels by graft polymerization of gelatin (Gel) and hydroxypropyl methyl cellulose (HPMC) in the presence of glutaraldehyde (GA) using quetiapine fumarate for the treatment of schizophrenia. The prepared hydrogels discs were subjected to various physicochemical studies

Full Text available with Trip Pro

2018 Drug delivery

31. Quetiapine-related Acute Kidney Injury Requiring Transient Continuous Hemodiafiltration (PubMed)

Quetiapine-related Acute Kidney Injury Requiring Transient Continuous Hemodiafiltration A 73-year-old man, with congestive heart failure due to combined valvar disease, underwent curative surgery. Although the surgery was successful, his clinical course was eventful because of pulmonary complications, and he began to deteriorate mentally. Quetiapine was prescribed, which appeared to effectively settle his mental status. Following the administration of quetiapine, however, he developed acute (...) kidney injury (AKI) that required continuous hemodiafiltration. Subsequent to discontinuation of quetiapine, his renal function gradually improved. Atypical antipsychotic drugs, including quetiapine, are frequently used to treat delirium in elderly patients in the intensive-care setting. This case highlights a potential risk of quetiapine-related AKI.

Full Text available with Trip Pro

2018 Internal Medicine

32. Results from a drug utilization study of extended release quetiapine fumarate prescribed by psychiatrists as treatment for major depressive disorder in selected countries in the European Union (PubMed)

Results from a drug utilization study of extended release quetiapine fumarate prescribed by psychiatrists as treatment for major depressive disorder in selected countries in the European Union This multicenter, observational drug utilization (DU) study (NCT01594996) investigated the profile of patients and specialist providers who prescribed extended release quetiapine fumarate (quetiapine XR) for treatment of major depressive disorder (MDD) across five European countries (Germany, Italy (...) , Romania, Spain, and Sweden). A DU data abstraction form captured information on the characteristics of physicians, patients, and drugs utilized in the medical management of depressive episodes in MDD, where the therapeutic regimen included quetiapine XR. Data were reported descriptively. This analysis included 811 patients. Psychiatric histories indicated a burden of severe MDD in these patients. Patient demographics were similar across countries; however, those in Sweden had a younger mean age

Full Text available with Trip Pro

2018 International clinical psychopharmacology

33. Quetiapine Related Acute Paralytic Ileus in a Bipolar I Disorder Patient with Successful Low Dose Amisulpride Substitution: A Case Report (PubMed)

Quetiapine Related Acute Paralytic Ileus in a Bipolar I Disorder Patient with Successful Low Dose Amisulpride Substitution: A Case Report The mechanism of medication-induced gastrointestinal hypomotility is primarily caused by muscarinic cholinergic antagonism. This effect may cause constipation and paralytic ileus, which may lead to fatal complications. A 51-year-old woman was admitted due to manic episode recurrence. She developed paralytic ileus under quetiapine use and treated successfully

Full Text available with Trip Pro

2018 Clinical Psychopharmacology and Neuroscience

34. Blood-Based Lipidomics Approach to Evaluate Biomarkers Associated With Response to Olanzapine, Risperidone, and Quetiapine Treatment in Schizophrenia Patients (PubMed)

Blood-Based Lipidomics Approach to Evaluate Biomarkers Associated With Response to Olanzapine, Risperidone, and Quetiapine Treatment in Schizophrenia Patients This is the first study to identify lipidomic markers in plasma associated with response of acutely ill schizophrenia patients in response to specific antipsychotic treatments. The study population included 54 schizophrenia patients treated with antipsychotics for 6 weeks. Treatment led to significant improvement in positive and negative (...) symptoms for 34 patients with little or no improvement for 20 patients. In addition, 37 patients showed an increase in body mass index after the 6 week treatment period, consistent with effects on metabolism and the association of such effects with symptom improvement. Profiling of plasma samples taken prior to therapy using liquid chromatography tandem mass spectrometry (LC-MS/MS) resulted in identification of 38, 10, and 52 compounds associated with the olanzapine, risperidone, and quetiapine

Full Text available with Trip Pro

2018 Frontiers in Psychiatry

35. Delayed-Onset Seizure in a Mild Quetiapine Overdose: Report of a Case and Review of the Literature (PubMed)

Delayed-Onset Seizure in a Mild Quetiapine Overdose: Report of a Case and Review of the Literature Among atypical antipsychotics, quetiapine is commonly prescribed and considered to have a favorable side effect and safety profile. Here, we report the case of a patient who developed a generalized tonic-clonic seizure 28 hours following ingestion of 1,400 mg of quetiapine. Review of the literature identifies delayed-onset seizure as a potential complication of quetiapine overdose. Unique (...) to this case, delayed-onset seizures occurred in a patient with a relatively low dose of quetiapine and no obvious toxidrome, suggesting that this reaction may be an important consideration in the management of quetiapine overdose. The pharmacokinetics and pharmacodynamics of quetiapine may explain this unusual phenomenon.

Full Text available with Trip Pro

2018 Case reports in psychiatry

36. Low-Dose Quetiapine in the Treatment of SSRI-Induced Bruxism and Mandibular Dystonia: Case Series (PubMed)

Low-Dose Quetiapine in the Treatment of SSRI-Induced Bruxism and Mandibular Dystonia: Case Series Objective: Selective serotonin reuptake inhibitors (SSRIs) have been the most widely used psychopharmacological agents prescribed for depression worldwide. Some adverse effects of SSRI drugs on central nervous system are insomnia and bruxism. These drugs also affect sleep. Quetiapine is used as adjunctive therapy to antidepressants for the treatment of major depressive disorder (MDD). It is a low (...) - dose dibenzothiazepine with more potent 5-HT2 than D2 receptor-blocking properties that can be used to manage bruxism because of its antagonist effect on the 5-HT2 receptor. Cases: The cases were 5 patients who have recently been treated with SSRIs and presented with bruxism. Low- dose quetiapine (between 25 and 50 mg daily) was prescribed for the patients, and after a few days, they reported no bruxism and continued taking the medication. Conclusion: We found that quetiapine can improve bruxism

Full Text available with Trip Pro

2018 Iranian journal of psychiatry

37. Quetiapine Treatment for Pediatric Delirium

Quetiapine Treatment for Pediatric Delirium Quetiapine Treatment for Pediatric Delirium - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Quetiapine Treatment for Pediatric Delirium The safety and scientific (...) ): Rita Alvarez, Medical College of Wisconsin Study Details Study Description Go to Brief Summary: This is a prospective, double-blind, randomized controlled trial to begin determining the efficacy of quetiapine as a treatment for pediatric delirium in patients admitted to the pediatric intensive care unit (PICU) Condition or disease Intervention/treatment Phase Delirium Drug: Quetiapine Other: Placebo Phase 2 Phase 3 Detailed Description: Delirium is an acute syndrome with fluctuation in mental

2018 Clinical Trials

38. A Survey on Quetiapine Extended-release Tablets in Patients With Depression in Bipolar Disorder

A Survey on Quetiapine Extended-release Tablets in Patients With Depression in Bipolar Disorder A Survey on Quetiapine Extended-release Tablets in Patients With Depression in Bipolar Disorder - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one (...) or more studies before adding more. A Survey on Quetiapine Extended-release Tablets in Patients With Depression in Bipolar Disorder The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. of clinical studies and talk to your health care provider before participating. Read our for details. ClinicalTrials.gov Identifier: NCT03403790 Recruitment Status : Recruiting

2018 Clinical Trials

39. Bariatric Surgery and Pharmacokinetics of Quetiapine

Bariatric Surgery and Pharmacokinetics of Quetiapine Bariatric Surgery and Pharmacokinetics of Quetiapine - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Bariatric Surgery and Pharmacokinetics of Quetiapine (...) is so far known about how gastric bypass and sleeve gastrectomy impacts the biological availability of medication. In this study the pharmacokinetic effects of bariatric surgery on quetiapine are investigated. Condition or disease Intervention/treatment Obesity, Morbid Drug: Quetiapine Study Design Go to Layout table for study information Study Type : Observational Estimated Enrollment : 12 participants Observational Model: Case-Only Time Perspective: Prospective Official Title: Bariatric Surgery

2018 Clinical Trials

40. A Case of Neuroleptic Malignant Syndrome in a Profoundly Intellectually Disabled Patient with Successful Reintroduction of Antipsychotic Therapy with Quetiapine (PubMed)

A Case of Neuroleptic Malignant Syndrome in a Profoundly Intellectually Disabled Patient with Successful Reintroduction of Antipsychotic Therapy with Quetiapine Neuroleptic Malignant Syndrome (NMS) is a rare condition clinically characterized by muscle rigidity, hyperthermia, autonomic instability, and acute mental status change. NMS is most often associated with use of high-potency first-generation antipsychotic medications; though, other neuroleptics have been implicated as well. NMS can (...) then discuss our decision to reintroduce an atypical antipsychotic agent, quetiapine. This case illustrates the importance of early recognition of the signs and symptoms of NMS and the need to initiate treatment promptly in order to prevent complications, including death. This case also highlights the decision to resume antipsychotic pharmacotherapy after adequate resolution of NMS, demonstrating that it can be done so safely if started at low doses coupled with intensive monitoring of the patient.

Full Text available with Trip Pro

2018 Case reports in psychiatry

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>